Literature DB >> 33191806

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.

Kyle A Williams1, Youkyung S Roh1, Isabelle Brown1, Nishadh Sutaria1, Pegah Bakhshi1, Justin Choi1, Sylvie Gabriel2, Rajeev Chavda2, Shawn G Kwatra1.   

Abstract

Introduction: Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extensor surfaces of the extremities. PN has a profoundly negative impact on sleep and quality of life in patients with PN. There are currently no U.S. Food and Drug Administration-approved agents and patients are often recalcitrant to current therapies, highlighting the importance of further research into this severely debilitating condition. Areas covered: A PubMed search was conducted to find available literature on the pathophysiology and clinical management of PN. In this review article, we discuss the current understanding of the pathophysiology, recommended diagnostic approach, and treatment options available for PN. Expert opinion/commentary: PN is an extremely difficult condition to treat, because there is a lack of effective therapies available due to our limited understanding of its pathophysiology. Currently, available treatment options are often multimodal due to the intersection of neuroimmune etiologic factors in the pathogenesis of PN. Fortunately, as our knowledge of PN expands, novel treatments targeting specific molecular biomarkers of PN are emerging, providing hope to this long-suffering patient population.

Entities:  

Keywords:  Prurigo nodularis; clinical features; comorbidities; epidemiology; itch; physical exam; pruritus; symptoms

Mesh:

Substances:

Year:  2020        PMID: 33191806     DOI: 10.1080/17512433.2021.1852080

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  8 in total

1.  Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series.

Authors:  Louise Lönndahl; Maria Lundqvist; Maria Bradley; Emma K Johansson
Journal:  Acta Derm Venereol       Date:  2022-08-11       Impact factor: 3.875

Review 2.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

3.  Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans.

Authors:  Nishadh Sutaria; Martin Prince Alphonse; Melika Marani; Varsha Parthasarathy; Junwen Deng; Shannon Wongvibulsin; Kyle Williams; Youkyung Sophie Roh; Justin Choi; Zachary Bordeaux; Thomas Pritchard; Carly Dillen; Yevgeniy R Semenov; Madan M Kwatra; Nathan K Archer; Luis A Garza; Xinzhong Dong; Sewon Kang; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-10-27       Impact factor: 7.590

Review 4.  Immunotargets and Therapy for Prurigo Nodularis.

Authors:  Angelina Labib; Teresa Ju; Ashley Vander Does; Gil Yosipovitch
Journal:  Immunotargets Ther       Date:  2022-04-26

5.  Tofacitinib for Prurigo Nodularis: A Case Report.

Authors:  Tianhao Li; Pingsheng Hao; Changlan Peng; Chunxiao Li; Yingying Zhou; Qiuyue Wang; Ping Xie
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-21

6.  Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series.

Authors:  Nana Luo; Qiuyue Wang; Min Lei; Tianhao Li; Pingsheng Hao
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-12

Review 7.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20

Review 8.  Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions-Precision Dermatology.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.